Efficacy of Hemopatch in Controlling of Postoperative Bleeding or Reducing of Postperative Morbidity After Laparoscopic Cholecistectomy Clinical Trial
Official title:
Efficacy of Hemopatch in Reducing of Postoperative Bleeding After Laparoscopic Cholecystectomy: Prosective and Multicenter Study
Demonstrate the effectiveness to Hemopatch in controlling postoperative bleeding or reducing of postperative fluid collection after laparoscopic cholecistectomy, morbidity and postoperative hospital stay.
Prospective Multicenter Longitudinal and cohort. The sample size of 150 patients was
calculated in order to obtain a statistical power adequacy or higher (Type I error - Alpha =
0.05, Type II Error - Beta = 0:20), assuming the 1-day to reduce the postoperative stay with
use Hemopatch compared to the control (average stay little 3 +/- 2 days).
Primary endpoint:
- significant reduction in postoperative hospital stay
Secondary endpoints:
- reduction of subhepatic blood liquid volume
- reduction of liver hematoma
- reduction of postooperative complications as deep surgical site
- reduction rates of reoperation
- reduction in readmission rates
- postoperative pain on the VAS scale 1-10.
The results obtained in relation to primary and secondary objectives will be compared with a
control group of case-matched.
Inclusion Criteria:
- Between the ages of 18-75 years, calculus of gallbladder (micro- and macro-lithiasis),
polyp/neoplasm of gallbladder
Exclusion Criteria:
- Coagulopathies, medication with antiplatelet drugs, ASA > 3, acute cholecystitis,
simultaneous calculus of main biliary duct, acute pancreatitis.
The patient will enroll if cholecystectomy is performed laparoscopically, if it is not a
complication occurred intraoperative type: iatrogenic enterotomy suture intestinal,
iatrogenic lesion of liver parenchyma, bile duct injury. The patient will exclude from the
study if one of these intraoperative complication will occur. The patient leaves the
protocol if the dissection is done through energy-devices (ultrasound or radiofrequency).
At the end of the laparoscopic cholecstectomy, Hemopatch will be inserted into the
peritoneal cavity through the port of 10-12 mm and laid on the cavity of the gallbladder and
a drainage will be systematically placed.
It will be given a first-generation cephalosporin antibiotic (one shot).
At 24 hours of VLC a liver ultrasound will be performed and recorded: evaluation of presence
of perihepatic fluid, collection or haematoma. It will be noted the volume of drainage which
will be removed in first postoperative day. In case of delay removal of drainage, it will be
recorded. It will be assessed postoperative pain by VAS scales to 6-12-24 h after surgery.
Re-operations and re-hospitalizations will be recorded in prospective data.
Statistical analyzes were performed using the software SPSS for Mac, 22nd edition (SPSS
Software, Inc., IL, Chicago). The differences in the distributions will be calculated using
the chi-square test or Fisher exact test, depending on the number of cases in the various
subgroups and by comparing means (Student t-test, one-way ANOVA test).
The p < 0.1 will be used as the cut-off for statistical significance in the selection of
variables of multivariate analysis in order not to drop important potential predictors.
The statistical significance is conventionally defined with p <0.05 in all cases considered.
All eligible patients will be adequately informed and informed consent will be signed. The
Study will be conducted according to ethical requirements, following the Declaration of
Helsinki, and good clinical practice.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention